Peer-reviewed veterinary case report
Safety and effects of IV pamidronate in 33 dogs with bone cancer
By Fan, Timothy M et al.·Published in Journal of veterinary internal medicine·2005·Department of Veterinary Clinical Medicine, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement.
- Species:
- dog
Plain-English summary
A group of 33 dogs with cancer affecting their bones were treated with an intravenous medication called pamidronate to see if it was safe and effective. Most dogs tolerated the treatment well, but one dog showed some kidney issues. In a smaller group of 10 dogs with a specific type of bone cancer, pamidronate helped reduce pain for some and improved bone density. Overall, pamidronate seems safe for dogs with cancer and may help manage bone-related problems caused by tumors.
People also search for: dog cancer treatment · pamidronate for dogs · bone cancer pain relief in dogs
Abstract
The purpose of this study was to evaluate the clinical safety of pamidronate when administered at a mean dosage of 1.0 mg/kg IV q28d in 33 tumor-bearing dogs. Biochemical tests of renal function were evaluated before each successive pamidronate treatment. Of 33 dogs treated with pamidronate, 1 dog had clinically relevant increases in serum creatinine and blood urea nitrogen concentrations. The biologic activity of IV pamidronate was assessed prospectively in 10 dogs with appendicular osteosarcoma and was assessed on reductions in urine N-telopeptide excretion (P = .042) and enhanced bone mineral density of the primary tumor measured with dual-energy x-ray absorptiometry (P = .024). Additionally, in these 10 dogs, pamidronate's therapeutic activity was supported by subjective improvement in pain control in 4 of the 10 dogs treated. IV pamidronate appears clinically safe in tumor-bearing dogs and may possess modest biologic activity for managing neoplastic complications associated with pathologic bone resorption.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/15715051/